Discover the groundbreaking research on how the overexpression of FKBP5 influences colorectal cancer progression and its potential as a target for FK506 treatment through the NF-κB signaling pathway.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Overexpressed FKBP5 mediates colorectal cancer progression and sensitivity to FK506 treatment via the NF-κB signaling pathway.
Liu et al., FEBS J 2024
<!– DOI: 10.1111/febs.17126 //–>
https://doi.org/10.1111/febs.17126
This study investigates the role of FK506-binding protein 5 (FKBP5) in colorectal cancer (CRC) and examines the therapeutic potential of FK506. Involving 96 CRC patients, the research found FKBP5 overexpressed in 77 cancer tissues, correlating with shorter overall survival. Through bioinformatics, immunohistochemistry, and various assays, FKBP5 was shown to regulate crucial processes like proliferation, invasion, and migration, primarily through the NF-κB signaling pathway. The study’s pivotal discovery is that FK506, by targeting FKBP5/NF-κB signaling, can inhibit CRC progression, suggesting FK506 as a promising drug for CRC treatment. This highlights FKBP5’s significant role in CRC and introduces FK506 as a potential novel therapeutic option, contributing to the understanding and management of CRC.